ArticlePloS one2014
Evaluation of nanolipoprotein particles (NLPs) as an in vivo delivery platform.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 47 citations in OpenAlex.
- Strategies for engineering biomimetic lipoproteins to improve drug delivery efficiency and tumor therapy.Drug delivery and translational research · 2026Review
- Distinct In Vitro Effects of Liposomal and Nanostructured Lipid Nanoformulations with Entrapped Acidic and Neutral Doxorubicin on B16-F10 Melanoma and Walker 256 Carcinoma Cells.Pharmaceutics · 2025Article
- Curcumin Nanodiscs Improve Solubility and Serve as Radiological Protectants against Ionizing Radiation Exposures in a Cell-Cycle Dependent Manner.Nanomaterials (Basel, Switzerland) · 2022Article
- Cell-free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development.Journal of visualized experiments : JoVE · 2022Article
- Transfer mechanism of cell-free synthesized membrane proteins into mammalian cells.Frontiers in bioengineering and biotechnology · 2022Article
- Demystifying mRNA vaccines: an emerging platform at the forefront of cryptic diseases.RNA biology · 2022Review
- Article
- Nanolipoprotein particles for co-delivery of cystine-knot peptides and Fab-based therapeutics.Nanoscale advances · 2021Article
- HIV influences microtubule associated protein-2: potential marker of HIV-associated neurocognitive disorders.AIDS (London, England) · 2020Article
- Cationic HDL mimetics enhance in vivo delivery of self-replicating mRNA.Nanomedicine : nanotechnology, biology, and medicine · 2020Article
- Characterization ofFrontiers in immunology · 2020Article
- Lipid and Protein Transfer between Nanolipoprotein Particles and Supported Lipid Bilayers.Langmuir : the ACS journal of surfaces and colloids · 2019Article
- Lipid composition dictates serum stability of reconstituted high-density lipoproteins: implications for in vivo applications.Nanoscale · 2018Article
- Nanodelivery of a functional membrane receptor to manipulate cellular phenotype.Scientific reports · 2018Article
- Reconstituted high-density lipoproteins: novel biomimetic nanocarriers for drug delivery.Acta pharmaceutica Sinica. B · 2018Review
- Selective Nanoparticle Targeting of the Renal Tubules.Hypertension (Dallas, Tex. : 1979) · 2018Article
- Cell-free production of a functional oligomeric form of aThe Journal of biological chemistry · 2017Article
- Facilitating Translational Nanomedicine via Predictive Safety Assessment.Molecular therapy : the journal of the American Society of Gene Therapy · 2017Review
- Lipoproteins and lipoprotein mimetics for imaging and drug delivery.Advanced drug delivery reviews · 2016Review
- High-Density Lipoproteins for Therapeutic Delivery Systems.Journal of materials chemistry. B · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanoparticles hold great promise for the delivery of therapeutics, yet limitations remain with regards to the use of these nanosystems for efficient long-lasting targeted delivery of therapeutics, including imparting functionality to the platform, in vivo stability, drug entrapment efficiency and toxicity. To begin to address these limitations, we evaluated the functionality, stability, cytotoxicity, toxicity, immunogenicity and in vivo biodistribution of nanolipoprotein particles (NLPs), which are mimetics of naturally occurring high-density lipoproteins (HDLs). We found that a wide range of molecules could be reliably conjugated to the NLP, including proteins, single-stranded DNA, and small molecules. The NLP was also found to be relatively stable in complex biological fluids and displayed no cytotoxicity in vitro at doses as high as 320 µg/ml. In addition, we observed that in vivo administration of the NLP daily for 14 consecutive days did not induce significant weight loss or result in lesions on excised organs. Furthermore, the NLPs did not display overt immunogenicity with respect to antibody generation. Finally, the biodistribution of the NLP in vivo was found to be highly dependent on the route of administration, where intranasal administration resulted in prolonged retention in the lung tissue. Although only a select number of NLP compositions were evaluated, the findings of this study suggest that the NLP platform holds promise for use as both a targeted and non-targeted in vivo delivery vehicle for a range of therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.